Gamida Cell Ltd.
Harey Yehuda 54
P.O.B. 94
Savyon
56530
Tel: 03-534-7482
Fax: 03-534-3067
218 articles about Gamida Cell Ltd.
-
Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma
6/18/2018
Gamida Cell announced that preliminary data from an ongoing phase I study from the nicotinamide-based natural killer cell expansion, or NAM-NK, program will be presented during the Inaugural AACR International Meeting on Advances in Malignant Lymphoma
-
Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting
4/30/2018
Gamida Cell announced that data from the company’s NiCord program will be presented during the International Society for Cellular Therapy (ISCT) Annual Meeting, held May 2-5 in Montreal.
-
Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing
4/26/2018
Mr. Hamermesh will lead the business operations and corporate development strategies for the company
-
Gamida Cell Appoints Shai Lankry as Chief Financial Officer
3/15/2018
Mr. Lankry brings more than a decade of senior management experience in finance at both public and private companies to his new role as CFO of Gamida Cell.
-
Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma
1/16/2018
Gamida Cell today announced the initiation of a phase I study evaluating its proprietary NAM-expanded natural killer cells (NAM-NK Cells) in patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (NHL) and multiple myeloma.
-
Gamida Cell Presents Data From Two Key Development Programs at the 2017 ASH Annual Meeting
12/12/2017
The study met its primary endpoint, demonstrating rapid neutrophil engraftment with manageable side effects.
-
Dr. Adams to further advance promising pipeline, including breakthrough therapy, NiCord, in phase 3 development as a universal bone marrow transplant solution.
-
Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting
11/2/2017
The oral presentations will highlight safety and efficacy data for a completed phase 2 study of the company’s lead clinical asset, NiCord, as a single cord blood graft, and proof-of-concept data for the advancement of natural killer cells (NK cells) as an immunotherapeutic modality for patients with cancer.
-
Gamida Cell Announces First Patient Transplanted In Phase I/II Study Of CordIn For Severe Aplastic Anemia And Hypoplastic MDS
8/21/2017
-
Gamida Cell Announces $3.5 Million Grant From The Israeli Government
7/20/2017
-
Gamida Cell Names Ronit Simantov, M.D. As Chief Medical Officer
7/10/2017
-
Israel's Gamida Cell Banks $40 Million For Bone Marrow Trial
6/19/2017
-
Gamida Cell Appoints Nobel Prize Laureate Professor Roger Kornberg And Immune Oncology Expert Dr. Michael Perry To Its Board Of Directors
6/5/2017
-
Gamida Cell Announces Publication Of Positive Clinical Outcomes From NiCord-Transplanted Patients In The Journal Of Biology Of Blood And Marrow Transplantation
4/20/2017
-
Gamida Cell Receives Additional EMA Orphan Drug Designation For Nicord In Haematopoietic Stem Cell Transplantation (HSCT)
3/23/2017
-
Gamida Cell Announces First Patient Transplanted In Phase III Registration Study Of Nicord For Blood Cancers
2/28/2017
-
Gamida Cell Presents Positive Data From Phase 1/2 Study Of NiCord as A Curative Treatment For Sickle Cell Disease At American Society of Hematology 2016
12/6/2016
-
Gamida Cell Names Julian Adams, Ph.D. New Chairman Of The Board
11/21/2016
-
Novartis AG-Backed Gamida Cell Nabs Breakthrough Tag for NiCord
10/11/2016
-
Gamida Cell Announces Appointment Of Julian Adams, Ph.D. And Kenneth I. Moch To Its Board Of Directors
9/15/2016